Scandinavian journal of infectious diseases
-
Scand. J. Infect. Dis. · Jan 2005
Case ReportsPseudomembranous tracheobronchitis caused by Aspergillus in immunocompromised patients.
We report 2 cases of Aspergillus pseudomembranous tracheobronchitis in patients with diabetes. The first patient succumbed to progressive obstructive respiratory failure despite mechanical ventilation and antifungal therapy. ⋯ Early bronchoscopy and histologic examination should be performed. Early, appropriate treatment may be life saving.
-
Scand. J. Infect. Dis. · Jan 2005
Review Case ReportsPacemaker infection due to Mycobacterium fortuitum.
Pacemaker infection with Mycobacterium fortuitum has not been reported previously. We describe a case of pacemaker generator pocket infection and intravascular lead endocarditis due to Mycobacterium fortuitum. The entire pacing system was removed and the patient was treated successfully with a multidrug regimen for a total of 6 months.
-
This is a report of the first recognized case of melioidosis in Nepal. Illness began 1 month after returning from Malaysia after a 1 y stay. The case highlights the importance of ascertaining the travel history in any patient with a suspected infectious disease in this age of global travel.
-
Scand. J. Infect. Dis. · Jan 2005
Case ReportsSuccessful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens.
We present a 49-y-old male, with a history of Marfan's disease and aortic and mitral valve replacement surgery, who was operated for a type III thoracoabdominal aneurysm. The postoperative course was compromised by a Staphylococcus epidermidis mitral valve endocarditis, which was successfully treated only after intravenous linezolid was included in the therapy.
-
Scand. J. Infect. Dis. · Jan 2005
Case ReportsDrotrecogin alpha (activated) in neonatal septic shock.
A 12-d-old neonate suffering from group B streptococcal septic shock was treated with 24 microg/kg/h recombinant human activated protein C [rhAPC, drotrecogin alpha (activated)] for 96 h. The protein C activity increased from 5% to 53% after rhAPC infusion. The patient recovered within 14 d without any adverse effects.